A trial to examine the effect of intensive UA-lowering therapy in patients with CKD and hyperuricemia - A trial to examine the effect of intensive UA-lowering therapy in patients with CKD and hyperuricemia(TARGET-UA)

ara medical Univ0 个研究点目标入组 370 人开始时间: 2017年3月28日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Excluding criteria 1. History of hypersensitivity to topiroxostat 2. Being treated with either febuxostat or topiraxostat 3. History of repeated gouty arthritis attack 4. History of attacks of urinary stone within 6 months 5. Obstructive urinary tract disorders 6. Primary or secondary hyperuricemia (congenital myogenic hyperuricemia, hematopoietic tumor, solid tumor, secondary polycythemia, hemolytic anemia, tumor lysis syndrome, rhabdomyolysis, multiple sclerosis, multiple juvenile gout nephropathy, polycystic kidney etc.) 7. active malignancy 8. Severe hepatic dysfunctions (transaminase >= 100 IU / L) 9. Poorly controlled diabetes mellitus (HbA1c> 8.4%) 10. Severe hypertension (sBP >= 180 mm Hg or dBP >= 110 mm Hg) 11. Pregnant patients / lactating patients, female patients who wish to become pregnant during the study 12. Being or supposed to be under medication with mercaptopurine hydrate and azathioprine that are contraindicated with topiroxostat. 13. Any antihypertensive drugs have been changed within a month or will be changed after the trial registration 14. Currently participating in other intervention studies (no restrictions are applied to participation in other observational study) 15. Suffering acute illnesses that may affect the effectiveness and safety until the main registration after primary registration 16. The participation to this study is judged inappropriate by the attending physicianto

发起方

ara medical Univ